Selvigaltin (GB1211), an orally accessible small molecule galectin-3 inhibitor developed being a treatment for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and safety to deal with regulatory specifications. Desk four Statistical assessment of dose proportionality of the pharmacokinetic parameters of GB1211 https://selvigaltin-oral-small-mo24578.blognody.com/46043874/how-selvigaltin-can-save-you-time-stress-and-money